News

Nasdaq1mon
Centessa Pharmaceuticals to Present Phase 1 Clinical Data of OX2R Agonist ORX750 at AAN 2025 Annual Meeting
Centessa Pharmaceuticals plc has announced that it will present data from a Phase 1 clinical trial of ORX750, a novel OX2R agonist being developed for narcolepsy type 1, narcolepsy type 2 ...
Yahoo Finance22d
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and IH ...
Finanznachrichten1mon
Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 ...
Finanznachrichten3mon
Alkermes plc: Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and IH ...